STAT+: Gilead drug prolongs survival of women with common form of breast cancer

Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30% — a clinical trial result that could lead to a better treatment option for patients with advanced disease and strengthen the drug’s commercial outlook.

In the study, called TROPICS-02, Trodelvy showed a median overall survival of 14.4 months compared to 11.2 months for comparator chemotherapy. The survival benefit of 3.2 months was statistically significant and translated into a 21% reduction in the risk of death.

Continue to STAT+ to read the full story…